349453-83-4Relevant academic research and scientific papers
Discovery, Modeling, and Human Pharmacokinetics of N-(2-Acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl) -thiophene-2-carboxamide (TBC3711), a Second Generation, ETA Selective, and Orally Bioavailable Endothelin Antagonist
Wu, Chengde,Decker, E. Radford,Blok, Natalie,Bui, Huong,You, Tony J.,Wang, Junmei,Bourgoyne, Andree R.,Knowles, Vippra,Berens, Kurt L.,Holland, George W.,Brock, Tommy A.,Dixon, Richard A. F.
, p. 1969 - 1986 (2007/10/03)
Sitaxsentan (1) (Wu et al. J. Med. Chem. 1997, 40, 1690) is our first endothelin antagonist being evaluated in clinical trials. It has demonstrated biological effects in an acute hemodynamic study in CHF (Givertz et al. Circulation 2000, 101, 2922), an op
